FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979581330> ?p ?o ?g. }

• W2979581330 endingPage "1290" @default.
• W2979581330 startingPage "1290" @default.
• W2979581330 abstract "Abstract Rituximab (R) is an active and well tolerated agent in the treatment of Waldenstrom’s Macroglobulinemia (WM) whether used in untreated or in refractory/relapsed pts. Furthermore, there is evidence that the association of R with chemotherapy may improve the quality of responses. Fludarabine and Cyclophosphamide (FC) are synergistic with R in vitro in lymphoma cell lines, and the administration of the three drugs is associated with higher response rates in other lymphoprolipherative disorders. We updated our experience to define the efficacy and tolerability of FCR in symptomatic pts with WM. Patients: Nineteen pts, median age 57 y, received R 375 mg/sqm iv d 1, F 25 mg/sqm iv d 2–4, C 250 mg/sqm iv d 2–4 every 4 weeks. Anti-infective prophylaxis with cotrimoxazole and acyclovir was administered. Median time from diagnosis to FCR treatment was 46 m (range 1–156). Five pts received FCR as first line treatment while 14 pts, of whom 8 refractory, had been previously treated with a median of 2 lines of therapy (range 1–6), 5 having previous received monoclonal antibodies. Splenomegaly and lymphadenopathy were present in 32% and 36% of pts, respectively. In 42% of cases Hb was <10g/dL, in 32% serum albumin was <3,5 g/dL, and in 53% β2M >3mg/dL. IgM median level was 4015 mg/dL (range 277– 10900), being > 4000 mg/dL in 53% of pts. Three pts were HCV-RNA positive and presented with cryoglobulinemia. Results: Pts received a median of 6 courses (range 3–6). Responses according to the IInd International Workshop on WM, updated in 2006, were categorized as follows: 15 PR (79%), 3 SD (16%), 1 PD (5%). Eight of the 15 PR pts could be considered as in “near CR”. In fact, the new response category could be justified by the achievement of complete resolution of symptoms, of adenopathy/organomegaly on CT scan, absence of malignant cells at BM immunophenotype and hystology, with only a persistence of a positive serum immunofixation (median serum MC protein of 0.3 g/dL). None of the variables considered (splenomegaly, lymphadenopathy, Hb level, serum albumin, β2M, IgM) was significantly associated with response. Ten pts showed a delayed response: 1 converted to CR after 4 m, in 9 a progressive reduction of MC is still detectable after a median follow-up of 10 m (range 4–31). Two pts underwent stem cell transplant (1 auto, 1 allo). Toxicity: Mild or moderate effects limited to the first and second R infusion, such as fever, hypotension, cutaneous rash, were seen in 5 pts (26%). None developed IgM “flare”. Neutropenia, observed in 82% of courses, was the main source of adverse effects. Two episodes of FUO and 1 clinically documented pneumonia were recorded. One pt died 3 m after the end of treatment while in PR for disseminated Aspegillosis. Conclusion: FCR regimen proved to be active and well tolerated even in previously heavily pre-treated WM pts; the response rate obtained is in line with clinical trials using R associated with other chemotherapeutic agents. A high percentage of near CRs and a progressive improvement of the quality of response has been observed even in pts with longer follow-up. The high incidence and long lasting episodes of neutropenia did not translate in major infectious episodes." @default.
• W2979581330 created "2019-10-18" @default.
• W2979581330 creator A5008054206 @default.
• W2979581330 creator A5018652598 @default.
• W2979581330 creator A5042609656 @default.
• W2979581330 creator A5045814742 @default.
• W2979581330 creator A5058904741 @default.
• W2979581330 creator A5061176005 @default.
• W2979581330 creator A5066134624 @default.
• W2979581330 creator A5071534708 @default.
• W2979581330 creator A5084359235 @default.
• W2979581330 date "2007-11-16" @default.
• W2979581330 modified "2023-09-26" @default.
• W2979581330 title "Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results" @default.
• W2979581330 doi "https://doi.org/10.1182/blood.v110.11.1290.1290" @default.
• W2979581330 hasPublicationYear "2007" @default.
• W2979581330 type Work @default.
• W2979581330 sameAs 2979581330 @default.
• W2979581330 citedByCount "8" @default.
• W2979581330 countsByYear W29795813302012 @default.
• W2979581330 crossrefType "journal-article" @default.
• W2979581330 hasAuthorship W2979581330A5008054206 @default.
• W2979581330 hasAuthorship W2979581330A5018652598 @default.
• W2979581330 hasAuthorship W2979581330A5042609656 @default.
• W2979581330 hasAuthorship W2979581330A5045814742 @default.
• W2979581330 hasAuthorship W2979581330A5058904741 @default.
• W2979581330 hasAuthorship W2979581330A5061176005 @default.
• W2979581330 hasAuthorship W2979581330A5066134624 @default.
• W2979581330 hasAuthorship W2979581330A5071534708 @default.
• W2979581330 hasAuthorship W2979581330A5084359235 @default.
• W2979581330 hasConcept C121332964 @default.
• W2979581330 hasConcept C126322002 @default.
• W2979581330 hasConcept C141071460 @default.
• W2979581330 hasConcept C142424586 @default.
• W2979581330 hasConcept C197934379 @default.
• W2979581330 hasConcept C203014093 @default.
• W2979581330 hasConcept C2776364478 @default.
• W2979581330 hasConcept C2776391228 @default.
• W2979581330 hasConcept C2776694085 @default.
• W2979581330 hasConcept C2776755627 @default.
• W2979581330 hasConcept C2778375690 @default.
• W2979581330 hasConcept C2779263901 @default.
• W2979581330 hasConcept C2779338263 @default.
• W2979581330 hasConcept C2780653079 @default.
• W2979581330 hasConcept C2781038049 @default.
• W2979581330 hasConcept C2781413609 @default.
• W2979581330 hasConcept C71924100 @default.
• W2979581330 hasConcept C87355193 @default.
• W2979581330 hasConcept C90924648 @default.
• W2979581330 hasConceptScore W2979581330C121332964 @default.
• W2979581330 hasConceptScore W2979581330C126322002 @default.
• W2979581330 hasConceptScore W2979581330C141071460 @default.
• W2979581330 hasConceptScore W2979581330C142424586 @default.
• W2979581330 hasConceptScore W2979581330C197934379 @default.
• W2979581330 hasConceptScore W2979581330C203014093 @default.
• W2979581330 hasConceptScore W2979581330C2776364478 @default.
• W2979581330 hasConceptScore W2979581330C2776391228 @default.
• W2979581330 hasConceptScore W2979581330C2776694085 @default.
• W2979581330 hasConceptScore W2979581330C2776755627 @default.
• W2979581330 hasConceptScore W2979581330C2778375690 @default.
• W2979581330 hasConceptScore W2979581330C2779263901 @default.
• W2979581330 hasConceptScore W2979581330C2779338263 @default.
• W2979581330 hasConceptScore W2979581330C2780653079 @default.
• W2979581330 hasConceptScore W2979581330C2781038049 @default.
• W2979581330 hasConceptScore W2979581330C2781413609 @default.
• W2979581330 hasConceptScore W2979581330C71924100 @default.
• W2979581330 hasConceptScore W2979581330C87355193 @default.
• W2979581330 hasConceptScore W2979581330C90924648 @default.
• W2979581330 hasIssue "11" @default.
• W2979581330 hasLocation W29795813301 @default.
• W2979581330 hasOpenAccess W2979581330 @default.
• W2979581330 hasPrimaryLocation W29795813301 @default.
• W2979581330 hasRelatedWork W1600780397 @default.
• W2979581330 hasRelatedWork W1969546598 @default.
• W2979581330 hasRelatedWork W1979810955 @default.
• W2979581330 hasRelatedWork W2053682062 @default.
• W2979581330 hasRelatedWork W2059608955 @default.
• W2979581330 hasRelatedWork W2092104080 @default.
• W2979581330 hasRelatedWork W2362661449 @default.
• W2979581330 hasRelatedWork W2413757434 @default.
• W2979581330 hasRelatedWork W2535477972 @default.
• W2979581330 hasRelatedWork W59295771 @default.
• W2979581330 hasVolume "110" @default.
• W2979581330 isParatext "false" @default.
• W2979581330 isRetracted "false" @default.
• W2979581330 magId "2979581330" @default.
• W2979581330 workType "article" @default.